Subtle Medical Rewrites the Physics of Medical Imaging by Making Existing Scanners Faster and Safer

Inside every MRI suite sits a constraint that radiologists have accepted as immutable: image quality depends on scan time, and scan time depends on the physics of signal acquisition. To obtain clearer images, patients must lie still longer. To reduce motion artifacts, protocols must be extended. To accommodate anxious or claustrophobic patients, sedation becomes necessary. These tradeoffs have shaped radiology workflows for decades, and the resulting bottlenecks limited scanner throughput, patient discomfort, and long appointment queues have been treated as the cost of doing business in medical imaging.

Subtle Medical was founded to challenge that assumption. Born out of Stanford University by neuroradiologist Dr. Greg Zaharchuk and deep learning scientist Enhao Gong, the company applies deep learning not to image interpretation but to image acquisition itself. Its vendor-neutral software solutions improve image quality on accelerated protocols, enabling significantly faster MRI, PET, and CT scans on the scanners hospitals already own. With 11 FDA clearances, more than 30 issued or pending patents, 25+ peer-reviewed papers, and over $85 million raised, Subtle Medical has deployed its technology on more than 1,300 scanners across multiple countries.

The intelligence behind Subtle Medical's approach lies in its recognition that the most impactful AI in radiology may not be the algorithm that reads images, but the one that makes better images possible in the first place. By addressing the acquisition layer rather than the interpretation layer, the company creates value that compounds across every scan, every patient, and every scanner in a health system's fleet.

Accelerating MRI without Compromising Diagnostic Confidence

SubtleHD™ (MR) applies denoising and sharpening to dramatically improve image quality while enabling MRI sequences up to 80 percent faster on existing scanners, both old and new. For radiology departments facing growing demand and fixed scanner capacity, this acceleration translates directly into increased patient throughput without capital expenditure. A scanner performing 12 exams per day can potentially accommodate significantly more, improving both revenue per scanner and patient access. The clinical benefit is equally material: shorter scans reduce motion artifacts, decrease the need for sedation in pediatric and claustrophobic patients, and improve the overall patient experience.

PET Enhancement for Low-Count Imaging

SubtleHD™ (PET) applies the same deep learning approach to denoise low-count PET data, enabling up to 75 percent faster scans with any commercial radiotracer across existing PET, PET/CT, and PET/MR scanners. PET imaging has traditionally required longer acquisition times to achieve adequate count statistics, and reduced tracer doses compromise image quality. By enhancing low-count data, Subtle Medical allows departments to reduce scan duration or lower radiotracer dosage while maintaining diagnostic quality an outcome with implications for both patient safety and operational efficiency.

CT Denoising for Improved Low-Contrast Detectability

SubtleHD™ (CT) reduces noise and improves low-contrast detectability on any existing CT or PET/CT scanner. Low-contrast lesions represent one of the most challenging detection tasks in CT interpretation, and image noise directly degrades radiologist confidence. By improving signal quality without requiring protocol changes or hardware upgrades, the solution supports more reliable diagnostic performance across a health system's installed CT base.

The Subtle-ELITE™ Suite as a Platform Strategy

The Subtle-ELITE™ suite represents the company's most advanced MRI offering, combining SubtleHD™ (MR), SubtleSYNTH™, and SubtleALIGN™ into an integrated package. SubtleSYNTH™ generates MR contrasts synthetically, achieving 100 percent acceleration and producing STIR images without additional acquisition time. SubtleALIGN™ automates brain MR alignment, reducing manual technologist adjustments and improving consistency across serial exams. This suite approach increases average revenue per scanner while positioning Subtle Medical as a platform vendor rather than a single-product supplier deepening account relationships and expanding expansion revenue within existing customers.

Partnerships That Extend Commercial Reach

Subtle Medical has cultivated strategic partnerships with major imaging stakeholders including Bracco Imaging, whose AiMIFY™ solution is powered by Subtle technology, and Bayer Pharmaceuticals, with whom the company is conducting clinical trials to reduce gadolinium dosage by up to 90 percent. These partnerships extend Subtle Medical's commercial reach into channels it could not access independently while validating its technology against the rigorous standards of global pharmaceutical and contrast media leaders.

The Economics of Software-Defined Imaging

Subtle Medical's growth reflects a structural shift in radiology economics: health systems cannot indefinitely purchase new scanners to meet rising imaging demand. Software that improves the performance of existing capital equipment offers a more capital-efficient path to capacity expansion. With over 1,300 scanners deployed and a portfolio spanning MRI, PET, and CT, the company has established itself as a leader in AI-powered image acquisition. As imaging volumes continue to rise and reimbursement pressures intensify, the value of acquisition-layer intelligence compounds.

Ohad Arazi, Chief Executive Officer

"Every human being deserves the opportunity for a timely diagnosis and high-quality care. Subtle Medical exists because the fastest path to better imaging is not always a new scanner it is smarter software on the scanners already in place."